Please login to the form below

Not currently logged in
Email:
Password:

oral antiviral drug

This page shows the latest oral antiviral drug news and features for those working in and with pharma, biotech and healthcare.

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2. ... PBI-045 – Pardes’ lead oral antiviral drug candidate – is designed to inhibit the main protease (Mpro) of SARS-CoV-2, the virus which causes

Latest news

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...